Published in Proc Natl Acad Sci U S A on July 29, 2008
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One (2009) 2.11
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev (2011) 1.71
Translational control in cancer etiology. Cold Spring Harb Perspect Biol (2013) 1.71
Altering chemosensitivity by modulating translation elongation. PLoS One (2009) 1.68
Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res (2011) 1.53
MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J (2010) 1.49
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med (2011) 1.45
Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev (2012) 1.43
The cancerous translation apparatus. Curr Opin Genet Dev (2011) 1.38
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
Mitochondrion-dependent N-terminal processing of outer membrane Mcl-1 protein removes an essential Mule/Lasu1 protein-binding site. J Biol Chem (2011) 1.31
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A (2010) 1.30
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21
Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue. J Bioenerg Biomembr (2009) 1.20
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest (2010) 1.18
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell (2011) 1.17
Evading apoptosis in cancer. Trends Cell Biol (2013) 1.17
Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer (2011) 1.14
A cellular response linking eIF4AI activity to eIF4AII transcription. RNA (2012) 1.13
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep (2012) 1.12
Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc Res (2009) 1.09
Targeting translation dependence in cancer. Oncotarget (2011) 1.09
Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells (2014) 1.09
MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer (2013) 1.07
Programming cancer cells for high expression levels of Mcl1. EMBO Rep (2013) 1.06
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One (2012) 1.03
Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther (2011) 1.03
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood (2013) 1.02
Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint. Mol Cell Biol (2011) 1.02
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica (2009) 1.01
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov (2012) 1.01
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med (2013) 1.01
The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep (2015) 1.01
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A (2015) 0.96
Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget (2015) 0.96
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One (2012) 0.95
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. PLoS One (2013) 0.95
Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol Cancer Res (2012) 0.94
Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J (2013) 0.94
Parkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol Cell Biol (2013) 0.93
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget (2015) 0.93
Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk Res (2011) 0.93
RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. Blood (2013) 0.93
The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer (2014) 0.93
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep (2012) 0.93
Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle (2009) 0.92
Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1. Int J Mol Sci (2014) 0.92
Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One (2012) 0.91
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia (2012) 0.91
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. Oncogene (2011) 0.89
Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis (2012) 0.88
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood (2016) 0.87
Genome-scale RNAi on living-cell microarrays identifies novel regulators of Drosophila melanogaster TORC1-S6K pathway signaling. Genome Res (2011) 0.87
Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells. J Clin Biochem Nutr (2013) 0.86
Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J (2015) 0.86
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell Death Dis (2014) 0.85
EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nat Cell Biol (2015) 0.84
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res (2014) 0.84
mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Mol Cell Biol (2015) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther (2012) 0.83
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther (2014) 0.83
Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene (2015) 0.83
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia (2015) 0.82
Genome-wide search for exonic variants affecting translational efficiency. Nat Commun (2013) 0.82
MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget (2015) 0.82
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell (2016) 0.81
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget (2015) 0.80
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene (2015) 0.80
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitus. Curr Diabetes Rev (2015) 0.80
Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine (2016) 0.79
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. Oncotarget (2015) 0.79
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget (2015) 0.79
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma (2014) 0.79
Modulation of tumor tolerance in primary central nervous system malignancies. Clin Dev Immunol (2012) 0.79
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med (Berl) (2013) 0.78
Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer (2016) 0.78
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. BMC Cancer (2015) 0.78
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget (2015) 0.77
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. Oncotarget (2016) 0.77
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Manag Res (2010) 0.77
The androgen receptor mediates antiapoptotic function in myometrial cells. Cell Death Dis (2014) 0.77
Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer. Oncol Rep (2015) 0.77
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica (2015) 0.77
Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2. PLoS One (2017) 0.76
Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation. Apoptosis (2015) 0.76
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. Sci Rep (2016) 0.75
Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics. Oncotarget (2016) 0.75
Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma. Am J Cancer Res (2016) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature (2003) 6.78
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev (2003) 6.17
Gene-specific regulation by general translation factors. Cell (2002) 6.05
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 5.94
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem (2006) 4.28
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell (2006) 3.83
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 3.02
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res (2006) 1.84
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene (2007) 1.46
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (2005) 6.86
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Short RNAs repress translation after initiation in mammalian cells. Mol Cell (2006) 6.70
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
Statistical practice in high-throughput screening data analysis. Nat Biotechnol (2006) 5.85
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Cyclin E ablation in the mouse. Cell (2003) 5.58
Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron (2009) 5.50
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science (2008) 5.36
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell (2006) 4.74
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
The microcosmos of cancer. Nature (2012) 4.50
Control of apoptosis by p53. Oncogene (2003) 4.46
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol (2004) 4.17
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol (2004) 3.99
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol (2006) 3.89
The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A (2005) 3.84
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature (2003) 3.77
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
Apoptosis and melanoma chemoresistance. Oncogene (2003) 3.58
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell (2007) 3.46
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol (2010) 3.33
The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature (2002) 3.30
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell (2012) 3.20
Genome sequencing reveals insights into physiology and longevity of the naked mole rat. Nature (2011) 3.19
Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity (2003) 3.17
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res (2006) 3.06
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med (2004) 3.03
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Stem cells: The promises and perils of p53. Nature (2009) 3.01
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res (2005) 2.97
Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature (2004) 2.90
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Inhibition of ribosome recruitment induces stress granule formation independently of eukaryotic initiation factor 2alpha phosphorylation. Mol Biol Cell (2006) 2.84
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Digital genotyping and haplotyping with polymerase colonies. Proc Natl Acad Sci U S A (2003) 2.77
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
New Alström syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med (2005) 2.74
Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci (2003) 2.67
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Perp is a p63-regulated gene essential for epithelial integrity. Cell (2005) 2.58